HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
OBJECTIVE To evaluate the safety and efficacy of synthetic conjugated estrogens B ( SCE-B ; 0.3 mg/d ) for 12 weeks in the treatment of vulvovaginal atrophy in symptomatic , postmenopausal women . DESIGN Prospect i ve , r and omized , multicenter , double-blind , placebo-controlled trial . SETTING Forty-two participating sites in the United States . PATIENT(S ) Postmenopausal women with at least one moderate to severe symptom of vaginal atrophy . INTERVENTION(S ) Daily oral administration , in a r and omized , placebo-controlled setting , of SCE-B ( 0.3 mg ) or of placebo for 12 weeks . MAIN OUTCOME MEASURE(S ) Mean changes in vaginal maturation index , percentage of parabasal and superficial cells , vaginal pH , and severity of the most bothersome symptom ( MBS ) between baseline and predetermined time points were assessed . Safety and tolerability were evaluated . RESULT ( S ) A total of 310 women ( mean age , 58.6 y ) were enrolled .  Synthetic conjugated estrogens B yielded statistically significantly greater differences in vaginal maturation index and vaginal pH from baseline to the end of treatment . Vaginal dryness ( 44.4 % ) and pain during intercourse ( 30.2 % ) were the symptoms most commonly identified as the MBS . A statistically significant mean reduction in the severity of the MBS was noted for SCE-B. There were no clinical ly significant differences observed between the two groups for findings related to safety . CONCLUSION ( S ) Synthetic conjugated estrogens B ( 0.3 mg/d ) was effective in treating vulvovaginal atrophy in symptomatic postmenopausal women . Significant improvement was seen in vaginal maturation index , vaginal pH , and severity of MBS from baseline to the end of treatment
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .